BioDelivery Sciences and Meda Announce FDA Approval of Onsolis
July 16, 2009
RALEIGH, N.C.--(BUSINESS WIRE)--Jul 16, 2009 - BioDelivery Sciences
International, Inc. and Meda AB today announced approval from the U.S.
Food and Drug Administration (FDA) to market Onsolis (fentanyl buccal
soluble film), formerly referred to as BEMA Fentanyl, for the
management of breakthrough pain (BTP) in patients with cancer,
eighteen years of age and older, who are already receiving and who are
tolerant to opioid therapy for their underlying persistent cancer
pain.
RALEIGH, N.C.--(BUSINESS WIRE)--Jul 16, 2009 - BioDelivery Sciences
International, Inc. and Meda AB today announced approval from the U.S.
Food and Drug Administration (FDA) to market Onsolis (fentanyl buccal
soluble film), formerly referred to as BEMA Fentanyl, for the
management of breakthrough pain (BTP) in patients with cancer,
eighteen years of age and older, who are already receiving and who are
tolerant to opioid therapy for their underlying persistent cancer
pain.
Comentarios
Publicar un comentario